Tower Research Capital LLC TRC Acquires 828 Shares of Merus (NASDAQ:MRUS)

Tower Research Capital LLC TRC boosted its stake in shares of Merus (NASDAQ:MRUS) by 64.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,120 shares of the biotechnology company’s stock after acquiring an additional 828 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Merus were worth $58,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in MRUS. Quadrant Capital Group LLC boosted its holdings in shares of Merus by 37.7% in the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 343 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Merus by 142.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after buying an additional 867 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Merus by 10.8% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,446 shares of the biotechnology company’s stock valued at $317,000 after acquiring an additional 1,310 shares during the last quarter. BluePath Capital Management LLC bought a new position in Merus during the third quarter valued at $33,000. Finally, Exchange Traded Concepts LLC raised its stake in shares of Merus by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,459 shares during the period. 96.14% of the stock is owned by institutional investors.

Merus Trading Up 0.2 %

Shares of MRUS traded up $0.07 during mid-day trading on Monday, hitting $45.11. The company’s stock had a trading volume of 975,944 shares, compared to its average volume of 599,798. The company’s 50-day moving average is $45.02 and its 200-day moving average is $34.17. Merus has a 52-week low of $18.21 and a 52-week high of $52.03. The firm has a market capitalization of $2.65 billion, a price-to-earnings ratio of -14.84 and a beta of 1.10.

Merus (NASDAQ:MRUS) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.38). The company had revenue of $8.94 million for the quarter, compared to analysts’ expectations of $10.43 million. Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. As a group, sell-side analysts predict that Merus will post -3.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MRUS. BMO Capital Markets upped their price target on shares of Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. StockNews.com downgraded Merus from a “hold” rating to a “sell” rating in a report on Monday, March 4th. HC Wainwright upped their price objective on Merus from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. William Blair reiterated an “outperform” rating on shares of Merus in a research note on Monday, April 22nd. Finally, Truist Financial started coverage on shares of Merus in a research note on Thursday, March 28th. They set a “buy” rating and a $69.00 target price for the company. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.33.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.